Janssen Reports P-III Study (MARIPOSA-2) Results of Rybrevant (amivantamab-vmjw) for EGFR-Mutated Non-Small Cell Lung Cancer
Shots:
- The P-III study evaluating Rybrevant with/out lazertinib and CT vs CT alone in 657 patients with LA or metastatic EGFR ex19del or L858R substitution NSCLC
- The trial met its dual 1EPs & showed a significant and clinical PFS improvement in both experimental treatment arms with no new safety signals. The 2EPs incl. ORR as assessed by BICR, OS, DoR, time to subsequent therapy, PFS after first subsequent therapy (PFS2), and intracranial PFS.
- The company plans to submit these results for presentation at an upcoming scientific congress while the combination therapy is being evaluated in the P-III study (MARIPOSA) in a 1L setting for EGFR-mutated NSCLC. Rybrevant received accelerated approval from the US FDA for LA or metastatic NSCLC with EGFR exon 20 insertion mutations
Ref: PRNewswire | Image: Janssen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
